News and Trends 19 Apr 2023 Nanocages developed to deliver small interfering RNAs Small interfering RNAs (siRNAs) are novel therapeutics that can be used to treat a wide range of diseases. This has led to a growing demand for selective, efficient, and safe ways of delivering siRNA in cells. Now, in a cooperation between the universities of Amsterdam and Leiden in the Netherlands, researchers have developed dedicated molecular […] April 19, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2023 Complement Therapeutics raises €72M for eye condition gene therapy Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, has completed a €72 million ($78.7 million) Series A financing. The round was led by Gimv, a Belgian-based private equity and venture capital fund, co-led by Forbion as existing investor and further joined by BioGeneration Ventures (BGV), Panakes Partners, […] April 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Apr 2023 Swedish bacterial resistance study could pave road to new antibiotics A species of ordinary gut bacteria flourishes when the intestinal flora is knocked out by a course of antibiotics. Since the bacteria are naturally resistant to many antibiotics, this can cause problems. A study at Lund University in Sweden now shows how two molecular mechanisms can work together to make the bacterium extra resistant. “Using […] April 17, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Apr 2023 Aer Therapeutics raises $36M to tackle lung diseases Aer Therapeutics, a joint University College Dublin (UCD) and University of California, San Francisco (UCSF) biopharmaceutical spin-out company developing novel inhaled treatments for muco-obstructive lung diseases, has announced the closing of a $36 million Series A financing round.Funding was received from a syndicate of premier life science industry investors, including Canaan, OrbiMed, and Hatteras Venture […] April 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Apr 2023 Ghana becomes first country to approve University of Oxford malaria vaccine Ghana has granted full national licensure for the University of Oxford’s R21/Matrix-M malaria vaccine, marking the first regulatory clearance for the vaccine for use in any country. Developed by the University of Oxford, leveraging Novavax’s adjuvant technology, and manufactured and scaled up by the Serum Institute of India PvT Ltd (SIIPL), the vaccine has been […] April 17, 2023 - 4 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 14 Apr 2023 TORL BioTherapeutics launches with $158M to target cancer TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a $158 million Series B financing. TORL’s pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) were discovered in the laboratory of scientific co-founder Dennis Slamon, professor of medicine, and chief of […] April 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Apr 2023 Researchers explain how some lung tumors avoid immunotherapy The oncogenic activation of MYC, a critical gene in cancer progression, has the potential to identify lung cancer patients who may respond poorly to immunotherapy. This is the main conclusion of a study recently published by a team of researchers led by Montse Sanchez-Cespedes, principal investigator of the Cancer Genetics group at the Josep Carreras […] April 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Apr 2023 biomodal launches new multiomics sequencing technology biomodal, formerly known as Cambridge Epigenetix, has launched its new duet multiomics solution, which it says reveals the combinatorial power of genetic and epigenetic information from a single low volume sample. The duet multiomics solution is the world’s first single-base-resolution sequencing technology that enables the simultaneous phased reading of genetic and epigenetic information in a […] April 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Parkinson’s cure ‘inevitable’ after biomarker breakthrough The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced what it says is the ‘most significant breakthrough yet’ in the search for a Parkinson’s biomarker: a biological test for Parkinson’s disease. The test demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise. A paper on […] April 13, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Adaptyv Bio launches to ‘change protein engineering’ AI tools like ChatGPT are revolutionizing how the world generates text, images and code. In a similar way, machine learning algorithms and generative AI are upending traditional processes in life sciences and collapsing time frames in drug discovery and materials development. AlphaFold by DeepMind is probably the most well-known machine learning model in this space. […] April 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Alentis Therapeutics raises $105M for claudin platform Alentis Therapeutics is a clinical-stage biotech developing treatments for organ fibrosis and claudin-1 (CLDN1) positive tumors. The company has announced $105 million in Series C financing. The funding round was led by Jeito Capital, Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email